GlassScriptPhysician profile
James P Richmond
NPI 1184620288
$965.94
in general payments reported to CMS, 2019-2025
15 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $101 · 2021: $127 · 2022: $34.87 · 2023: $65.25 · 2024: $182 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $176.71 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $175.57 | 2023-2025 | Acthar |
| Abbvie INC. | $167.26 | 2024-2025 | |
| Alcon Vision LLC | $87.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $70.23 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $70.15 | 2019-2021 | |
| Dompe US, INC. | $59.55 | 2025 | Oxervate |
| Omeros Corporation | $34.41 | 2019 | |
| Bausch & Lomb Americas INC. | $22.23 | 2023 | Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $20.73 | 2024 | Tecnis Iol |
| Ocular Therapeutix, INC. | $19.67 | 2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $17.20 | 2024 | |
| Ethicon US, LLC | $16.77 | 2025 | Stratafix, Surgicel Nu-Knit, Vistaseal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.14 | 2019 | |
| Alcon Research LLC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.